When symptom relief is consistent, each day has possibilities*

*For patients with COPD who seek symptom relief, YUPELRI is the first and only once-daily nebulized LAMA that delivers a full 24 hours of lung function improvement.1

GET TO KNOW YUPELRI
Use the icon to expand the subject area
 

Have you considered the role of nebulization in COPD maintenance therapy?

Nebulizers: a user-friendly option for COPD patients2

  • Nebulizers require only normal tidal breathing and do not require generating adequate inspiratory force3-5
  • No hand-breath coordination is needed3,6
  • Today’s nebulizers include compact, portable, and low-cost options for most patients7,20
LEARN MORE
 

Many of your patients may be candidates for nebulized therapy

Consider nebulized therapy for appropriate patients.

PATIENT TYPES
 

YUPELRI delivers consistent control* over 12 weeks. YUPELRI demonstrated consistent improvements† in trough FEV1 vs placebo over the 12-week study period.1,11

* In Study 1, LS mean change from baseline in trough FEV1 on day 85 was 127 mL (YUPELRI, n=189) and -19 mL (placebo, n=191), with a statistically significant difference vs placebo of 146 mL (P<.0001). In Study 2, LS mean change from baseline in trough FEV1 on day 85 was 102 mL (YUPELRI, n=181) and -45 mL (placebo, n=187), with a statistically significant difference of 147 mL (P<.0001).1,11

† The first measurement was taken at 2 weeks.

EFFICACY
Proven
24-hour control1
Responses as early as 30 minutes*
Once-daily
dosing1
Administered with any standard jet nebulizer with a mouthpiece
Demonstrated
safety profile1
Fewer discontinuations with YUPELRI (13%) vs placebo (19%) 1

*An exploratory analysis of the time to achieve a 100 mL increase in FEV1 on day 1 showed that the median time to achieve an increase in FEV1 of 100 mL was 30 minutes in Study 1 (30 to 60 minutes) and Study 2 (30 to 90 minutes).

Up to 100% of patients with Medicare Part B are covered.†

J-CODE J7677

LEARN MORE

†This is not a guarantee of coverage. Site of Care will determine coverage. Check with your patient’s insurance provider for coverage rules and restrictions. In certain limited instances, YUPELRI may be covered through a patient’s Medicare Part D pharmacy benefit.

Learn More

YUPELRI was studied in two 12-week, randomized, double-blind, placebo-controlled, parallel-group confirmatory studies (Studies 1 and 2) to evaluate the efficacy of YUPELRI vs placebo in patients with moderate to very severe COPD. See results here.

collapse collapse

Indication

collapse

YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

For additional information, please contact us at 1-800-395-3376.

For additional information, please contact us at 1-800-395-3376.